Singapore's Hyphens Pharma half-year profit jumps as margins improve

Hyphens Pharma International

13/08/2026 12:21

Overview
Singapore specialty pharma group's half-year revenue declined 0.5% yr/yr
Net profit after tax for 1H2026 surged 132.5% yr/yr
Gross profit margin improved due to portfolio optimization and higher-margin product focus

Outlook
Company to focus on growing higher-margin brands and supply chain efficiencies over next 12 months
Hyphens Pharma expects to scale Medical Aesthetics business selectively, emphasizing sustainable returns
Company remains exposed to FX volatility and will consider prudent pricing adjustments, hedging high-risk currencies

Result Drivers
PORTFOLIO OPTIMIZATION - Co said improved gross profit margin was driven by a shift to higher-margin products and portfolio rationalization
PROPRIETARY BRANDS GROWTH - Proprietary Brands segment revenue grew 17.9%, supported by portfolio expansion and higher demand for Ceradan and Ocean Health products
REDUCED FX AND INVENTORY LOSSES - Net profit benefited from a 68.5% reduction in foreign exchange translation losses and inventory obsolescence provision

Company press release: ID:nSN8W19wD

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
S$89.10 mln
 
H1 Net Income
 
S$4.60 mln
 
H1 Gross Profit
 
S$37.70 mln
 
H1 Pretax Profit
 
S$6.30 mln
 

Analyst Coverage
The one available analyst rating on the shares is "strong buy"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Hyphens Pharma International Ltd is S$0.42, about 12.2% above its August 13 closing price of S$0.37
The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 12 three months ago

Reuters Recommended Reads
Aug 12 - Singapore's Beverly JCG half-year revenue falls 32% on weaker aesthetic medical
Aug 13 - Singapore's Aoxin Q & M Dental HY revenue falls as patients dwindle; profit holds due to cost cuts
Aug 11 - Germany's Dermapharm prelim H1 revenue rises, maintains outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)